Evidence map›Paper›PMID 38338382›Full record

ArticleMolecules (Basel, Switzerland)2024

An Automated Micro Solid-Phase Extraction (μSPE) Liquid Chromatography-Mass Spectrometry Method for Cyclophosphamide and Iphosphamide: Biological Monitoring in Antineoplastic Drug (AD) Occupational Exposure.

Stefano Dugheri, Donato Squillaci, Valentina Saccomando, Giorgio Marrubini, Elisabetta Bucaletti, Ilaria Rapi, Niccolò Fanfani, Giovanni Cappelli, Nicola Mucci

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Stefano DugheriDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0002-3078-7188
Donato SquillaciDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0001-8665-845X
Valentina SaccomandoDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Giorgio MarrubiniDepartment of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0003-1399-5783
Elisabetta BucalettiDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-2060-5392
Ilaria RapiDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Niccolò FanfaniDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Giovanni CappelliDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.
Nicola MucciDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy.ORCID 0000-0003-0579-1035
University of Florence · ITUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the considerable steps taken in the last decade in the context of antineoplastic drug (AD) handling procedures, their mutagenic effect still poses a threat to healthcare personnel actively involved in compounding and administration units. Biological monitoring procedures usually require large volumes of sample and extraction solvents, or do not provide adequate sensitivity. It is here proposed a fast and automated method to evaluate the urinary levels of cyclophosphamide and iphosphamide, composed of a miniaturized solid phase extraction (µSPE) followed by ultrahigh-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) analysis. The extraction procedure, developed through design of experiments (DoE) on the ePrep One Workstation, required a total time of 9.5 min per sample, with recoveries of 77-79% and a solvent consumption lower than 1.5 mL per 1 mL of urine sample. Thanks to the UHPLC-MS/MS method, the limits of quantification (LOQ) obtained were lower than 10 pg/mL. The analytical procedure was successfully applied to 23 urine samples from compounding wards of four Italian hospitals, which resulted in contaminations between 27 and 182 pg/mL.

Indexed as

Antineoplastic AgentsOccupational ExposureBiological MonitoringChromatography, High Pressure LiquidCyclophosphamideIfosfamideLiquid Chromatography-Mass SpectrometrySolid Phase ExtractionSolventsTandem Mass SpectrometryAntineoplastic AgentsCyclophosphamideIfosfamideSolventsantineoplastic drugsbiological monitoringmicro solid phase extractiontandem mass spectrometryultrahigh-performance liquid chromatographyµSPEed

Identifiers

PMID38338382
PMCPMC10856084
OpenAlexW4391361528

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.